Literature DB >> 28854069

Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography After Concurrent Chemoradiotherapy in Locally Advanced Head-and-Neck Squamous Cell Cancer: The ECLYPS Study.

Tim Van den Wyngaert1, Nils Helsen1, Laurens Carp1, Sara Hakim1, Michel J Martens1, Isabel Hutsebaut1, Philip R Debruyne1, Annelies L M Maes1, Joost van Dinther1, Carl G Van Laer1, Otto S Hoekstra1, Remco De Bree1, Sabine A E Meersschout1, Olivier Lenssen1, Jan B Vermorken1, Danielle Van den Weyngaert1, Sigrid Stroobants1.   

Abstract

Purpose To assess the standardized implementation and reporting of surveillance [18F]fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) scan of the neck in locoregionally advanced head-and-neck squamous cell carcinoma (LAHNSCC) after concurrent chemoradiotherapy (CCRT). Patients and Methods We performed a prospective multicenter study of FDG-PET/CT scanning 12 weeks after CCRT in newly diagnosed patients with LAHNSCC (stage IVa/b) that used standardized reconstruction and Hopkins reporting criteria. The reference standard was histology or > 12 months of clinical follow-up. The primary outcome measure was the negative predictive value (NPV) of FDG-PET/CT scans and other supporting diagnostic test characteristics, including time dependency with increasing follow-up time. Results Of 152 patients, 125 had adequate primary tumor control after CCRT and entered follow-up (median, 20.4 months). Twenty-three (18.4%) had residual neck disease. Overall, NPV was 92.1% (95% CI, 86.9% to 95.3%; null hypothesis: NPV = 85%; P = .012) with sensitivity of 65.2% (95% CI, 44.9% to 81.2%), specificity of 91.2% (95% CI, 84.1% to 95.3%), positive predictive value of 62.5% (95% CI, 45.5% to 76.9%), and accuracy of 86.4% (95% CI, 79.3% to 91.3%). Sensitivity was time dependent and high for residual disease manifesting up to 9 months after imaging but lower (59.7%) for disease detected up to 12 months after imaging. Standardized reporting criteria reduced the number of equivocal reports (95% CI for the difference, 2.6% to 15.0%; P = .003). Test characteristics were not improved with the addition of lymph node CT morphology criteria. Conclusion FDG-PET/CT surveillance using Hopkins criteria 12 weeks after CCRT is reliable in LAHNSCC except for late manifesting residual disease, which may require an additional surveillance scan at 1 year after CCRT to be detected.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28854069     DOI: 10.1200/JCO.2017.73.5845

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  12 in total

1.  FDG-PET/CT in the surveillance of head and neck cancer following radiotherapy.

Authors:  Louise Madeleine Risør; Annika Loft; Anne Kiil Berthelsen; Frederik Cornelius Loft; Andreas Ruhvald Madsen; Ivan Richter Vogelius; Andreas Kjær; Jeppe Friborg
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-10-23       Impact factor: 2.503

2.  An IL-15-based superagonist ALT-803 enhances the NK cell response to cetuximab-treated squamous cell carcinoma of the head and neck.

Authors:  Ashley Pinette; Elizabeth McMichael; Nicholas B Courtney; Megan Duggan; Brooke N Benner; Fouad Choueiry; Lianbo Yu; David Abood; Thomas A Mace; William E Carson
Journal:  Cancer Immunol Immunother       Date:  2019-07-23       Impact factor: 6.968

Review 3.  Molecular Imaging in Oncology Using Positron Emission Tomography.

Authors:  Thorsten Derlin; Viktor Grünwald; Jörg Steinbach; Hans-Jürgen Wester; Tobias L Ross
Journal:  Dtsch Arztebl Int       Date:  2018-03-16       Impact factor: 5.594

4.  Head and neck tumors angiogenesis imaging with 68Ga-NODAGA-RGD in comparison to 18F-FDG PET/CT: a pilot study.

Authors:  Steve Durante; Vincent Dunet; François Gorostidi; Periklis Mitsakis; Niklaus Schaefer; Judith Delage; John O Prior
Journal:  EJNMMI Res       Date:  2020-05-07       Impact factor: 3.138

Review 5.  What is the prognostic impact of FDG PET in locally advanced head and neck squamous cell carcinoma treated with concomitant chemo-radiotherapy? A systematic review and meta-analysis.

Authors:  Pierluigi Bonomo; A Merlotti; E Olmetto; A Bianchi; I Desideri; A Bacigalupo; P Franco; C Franzese; E Orlandi; L Livi; S Caini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-06-09       Impact factor: 9.236

6.  Hopkins criteria for residual disease assessment after definitive radiotherapy in nasopharyngeal carcinoma.

Authors:  Yang Liu; Wen Long; Guannan Wang; Yuxiang Yang; Biaoshui Liu; Wei Fan
Journal:  Cancer Med       Date:  2019-12-25       Impact factor: 4.452

7.  18F-Fluorodeoxyglucose positron emission tomography may not visualize radiation pneumonitis.

Authors:  Meiying Guo; Liang Qi; Yun Zhang; Dongping Shang; Jinming Yu; Jinbo Yue
Journal:  EJNMMI Res       Date:  2019-12-19       Impact factor: 3.138

8.  Quantification of 18F-fluorodeoxyglucose uptake to detect residual nodal disease in locally advanced head and neck squamous cell carcinoma after chemoradiotherapy: results from the ECLYPS study.

Authors:  Nils Helsen; Tim Van den Wyngaert; Laurens Carp; Remco De Bree; Olivier M VanderVeken; Frank De Geeter; Alex Maes; Jean-Philippe Cambier; Karoline Spaepen; Michel Martens; Sara Hakim; Laurence Beels; Otto S Hoekstra; Danielle Van den Weyngaert; Sigrid Stroobants; Carl Van Laer; Pol Specenier; Annelies Maes; Philip Debruyne; Isabel Hutsebaut; Joost Van Dinter; Filip Homans; Laurence Goethals; Oliver Lenssen; Kristof Deben
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-02-10       Impact factor: 9.236

Review 9.  RESISTing the Need to Quantify: Putting Qualitative FDG-PET/CT Tumor Response Assessment Criteria into Daily Practice.

Authors:  J G Peacock; C T Christensen; K P Banks
Journal:  AJNR Am J Neuroradiol       Date:  2019-11-28       Impact factor: 4.966

10.  18 F-FDG PET/CT for response evaluation of regional lymph nodes in 97 head and neck squamous cell carcinoma patients: Differences in the predictive value of residual disease after radiotherapy and chemoradiotherapy.

Authors:  Saskia H Hanemaaijer; Maran Fazzi; Roel J H M Steenbakkers; Bart Dorgelo; Bert van der Vegt; Max J H Witjes; Bernard F A M van der Laan; Sjoukje F Oosting; Gilles N Stormezand; Boudewijn E C Plaat
Journal:  Clin Otolaryngol       Date:  2020-05-25       Impact factor: 2.597

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.